Standardized factor VIII (FVIII)-defιcient plasma is necessary for the clotting assay of this protein. Ethical considerations and prevalence of HIV seropositivity in hemophilia A patients have required the replacement of severe hemophilia A plasma by another specific substrate for FVIII clotting assays. FVIII-deficient plasma was prepared by immunodepletion using polyclonal anti-von-Willebrand factor (vWF) and monoclonal anti-FVIII antibodies coated to agarose beads. This plasma, deficient in both FVIII and vWF, allows the evaluation of FVIII activity with a detection limit of 1 % as compared to normal plasma. This immunodepleted plasma was compared to plasma from severe hemophilia A for the FVIII determination in plasma from normal subjects, severe and mild hemophiliacs, patients with von Willebrand disease and dicoumarol-treated patients. In all cases, similar values were obtained with both reagents at various levels of FVIII, with a correlation coefficient of 0.994. Such a good correlation was also obtained for the assay of FVIII in concentrates and in plasma from hemophiliacs following infusion. This immunodeficient plasma thus represents a suitable reagent for the FVIII clotting assay and provides an accurate alternative to the use of hemophilic plasma.

Keywords:
Factor VIII, Clotting assay, Deficient plasma, von Willebrand factor, Monoclonal antibodies, Hemophilia A, AIDS
This content is only available via PDF.
© 1990 S. Karger AG, Basel
1990
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.